Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition by Christakoudi, S. et al.
14 December 2021
AperTO - Archivio Istituzionale Open Access dell'Università di Torino
Original Citation:





(Article begins on next page)
Anyone can freely access the full text of works made available as "Open Access". Works made available under a
Creative Commons license can be used according to the terms and conditions of said license. Use of all other works
requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.
Availability:
This is the author's manuscript
This version is available http://hdl.handle.net/2318/1766491 since 2021-01-12T18:57:52Z
Blood Pressure and Risk of Cancer in the European Prospective 
Investigation into Cancer and Nutrition
Sofia Christakoudi#1,2, Artemisia Kakourou#3, Georgios Markozannes3, Ioanna Tzoulaki1,3, 
Elisabete Weiderpass4, Paul Brennan4, Marc Gunter4, Christina C. Dahm5, Kim Overvad5,6, 
Anja Olsen7, Anne Tjønneland7,8, Marie-Christine Boutron-Ruault9,10, Anne-Laure 
Madika9,10,11, Gianluca Severi9,10, Verena Katzke12, Tilman Kühn12, Manuela M. 
Bergmann13, Heiner Boeing13, Anna Karakatsani14,15, Georgia Martimianaki14, Paschalis 
Thriskos14, Giovanna Masala16, Sabina Sieri17, Salvatore Panico18, Rosario Tumino19, 
Fulvio Ricceri20,21, Antonio Agudo22, Daniel Redondo-Sánchez23,24, Sandra M. Colorado-
Yohar24,25,26, Olatz Mokoroa27, Olle Melander28, Tanja Stocks29, Christel Häggström30,31, 
Sophia Harlid32, Bas Bueno-de-Mesquita1,33,34,35, Carla H. van Gils36, Roel C.H. 
Vermeulen1,37,38, Kay-Tee Khaw39, Nicholas J. Wareham40, Tammy Y.N. Tong41, Heinz 
Freisling4, Mattias Johansson4, Hannah Lennon4, Dagfinn Aune1,42,43, Elio Riboli1, 
Dimitrios Trichopoulos†,14,44,45, Antonia Trichopoulou14, Konstantinos K. Tsilidis1,3
1Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, 
St Mary’s Campus, Norfolk place, London W2 1PG, United Kingdom 2MRC Centre for 
Transplantation, King’s College London, Great Maze Pond, London SE1 9RT, United Kingdom 
3Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, 
Greece 4International Agency for Research on Cancer, World Health Organization, 69372 Lyon 
CEDEX 08, France 5Department of Public Health, Aarhus University, DK-8000, Aarhus, Denmark 
6Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark 7Diet, Genes and 
Environment, Danish Cancer Society Research Center, DK-2100, Copenhagen, Denmark 
8Department of Public Health, Faculty of Health and Medical Sciences, University of 
Copenhagen, Copenhagen, Denmark 9Centre de recherche en Epidemiologie et Sante des 
Populations (CESP), Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, 
Université Paris-Saclay, 94805, Villejuif, France 10Gustave Roussy, F-94805, Villejuif, France 
11Université Lille, CHU Lille, EA2694, Lille, France 12Division of Cancer Epidemiology, German 
Cancer Research Center (DKFZ), Heidelberg, Germany 13Department of Epidemiology, German 
Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Arthur-Scheunert-Allee 114-116, 
Nuthetal, Germany 14Hellenic Health Foundation, Athens, Greece 152nd Pulmonary Medicine 
Department, School of Medicine, National and Kapodistrian University of Athens, “ATTIKON” 
University Hospital, Haidari, Greece 16Cancer Risk Factors and Life-Style Epidemiology Unit, 
Corresponding author: Sofia Christakoudi, PhD, Department of Epidemiology and Biostatistics, School of Public Health, Imperial 
College London, St Mary’s Campus, London, W2 1PG, UK. s.christakoudi@imperial.ac.uk.
†Deceased
Conflict of interest: The authors have no conflict of interest to declare.
Disclaimer 
Where authors are identified as personnel of the International Agency for Research on Cancer / World Health Organization, the 
authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views 
of the International Agency for Research on Cancer / World Health Organization.
Europe PMC Funders Group
Author Manuscript
Int J Cancer. Author manuscript; available in PMC 2020 November 15.
Published in final edited form as:













Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Florence, Italy 
17Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 
20133, Milano, Italy 18Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, 
Italy 19Cancer Registry and Histopathology Department, "M.P.Arezzo" Hospital, ASP Ragusa, 
Italy 20Department of Clinical and Biological Sciences, University of Turin, Italy 21Unit of 
Epidemiology, Regional Health Service ASL TO3, Grugliasco (TO), Italy 22Unit of Nutrition and 
Cancer. Cancer Epidemiology Research Program. Catalan Institute of Oncology-IDIBELL. 
L’Hospitalet de Llobregat, Barcelona, Spain 23Escuela Andaluza de Salud Pública. Instituto de 
Investigación Biosanitaria ibs.GRANADA, Universidad de Granada. Granada, Spain 24CIBER de 
Epidemiología y Salud Pública (CIBERESP), Madrid, Spain 25Department of Epidemiology, 
Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain 26Research Group on Demography 
and Health, National Faculty of Public Health, University of Antioquia, Medellín, Colombia 27Public 
Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain 28Department 
of Clinical Sciences Malmö, Lund University, Malmö, Sweden 29Department of Clinical Sciences 
Lund, Lund University, Lund, Sweden 30Department of Biobank Research, Umeå University, 
Umeå, Sweden 31Department of Surgical Sciences, Uppsala University, Uppsala, Sweden 
32Department of Radiation Sciences, Umeå University, Umeå, Sweden 33Dept. for Determinants 
of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), PO 
Box 1, 3720 BA Bilthoven, The Netherlands 34Department of Gastroenterology and Hepatology, 
University Medical Centre, Utrecht, The Netherlands 35Dept. of Social & Preventive Medicine, 
Faculty of Medicine, University of Malaya, Pantai Valley, 50603, Kuala Lumpur, Malaysia 
36Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University 
Medical Center, Utrecht, The Netherlands 37Environmental Epidemiology Group, Institute of Risk 
Assessment Sciences, Utrecht University, Utrecht, The Netherlands 38Public Health Department, 
University Medical Center, Utrecht, The Netherlands 39University of Cambridge, School of Clinical 
Medicine, Addenbrooke’s Hospital, Cambridge CB2 2QQ, United Kingdom 40MRC Epidemiology 
Unit, Institute of Metabolic Science, School of Clinical Medicine, University of Cambridge, 
Cambridge CB2 0QQ, United Kingdom 41Cancer Epidemiology Unit, Nuffield Department of 
Population Health, University of Oxford, Oxford. United Kingdom 42Department of Nutrition, 
Bjørknes University College, Oslo, Norway 43Department of Endocrinology, Morbid Obesity and 
Preventive Medicine, Oslo University Hospital, Oslo, Norway 44Department of Epidemiology, 
Harvard School of Public Health, Boston, MA, USA 45Bureau of Epidemiologic Research, 
Academy of Athens, Athens, Greece
# These authors contributed equally to this work.
Abstract
Several studies have reported associations of hypertension with cancer, but not all results were 
conclusive. We examined the association of systolic (SBP) and diastolic (DBP) blood pressure 
with the development of incident cancer at all anatomical sites in the European Prospective 
Investigation into Cancer and Nutrition (EPIC). Hazard ratios (HR) (95% confidence intervals) 
were estimated using multivariable Cox proportional hazards models, stratified by EPIC-
participating centre and age at recruitment, and adjusted for sex, education, smoking, body mass 
index, physical activity, diabetes and dietary (in women also reproductive) factors. The study 
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included 307,318 men and women, with an average follow-up of 13.7 (standard deviation 4.4) 
years and 39,298 incident cancers. We confirmed the expected positive association with renal cell 
carcinoma: HR=1.12 (1.08-1.17) per 10mmHg higher SBP and HR=1.23 (1.14-1.32) for DBP. We 
additionally found positive associations for esophageal squamous cell carcinoma (SCC): HR=1.16 
(1.07-1.26) (SBP), HR=1.31 (1.13-1.51) (DBP), weaker for head and neck cancers: HR=1.08 
(1.04-1.12) (SBP), HR=1.09 (1.01-1.17) (DBP) and, similarly, for skin SCC, colon cancer, post-
menopausal breast cancer and uterine adenocarcinoma (AC), but not for esophageal AC, lung 
SCC, lung AC, or uterine endometroid cancer. We observed weak inverse associations of SBP with 
cervical SCC: HR=0.91 (0.82-1.00) and lymphomas: HR=0.97 (0.93-1.00). There were no 
consistent associations with cancers in other locations.
Our results are largely compatible with published studies and support weak associations of blood 
pressure with cancers in specific locations and morphologies.
Keywords
cancer; hypertension; morphology; cohort; Europe; epidemiology; association; risk factors
Introduction
Hypertension and cancer are complex multifactorial conditions. Hypertension is a 
worldwide public health challenge, with systolic blood pressure (SBP) above 115mmHg 
ranked as the leading risk factor for the global burden of disease in 2017 [1]. The global age-
standardised prevalence of raised blood pressure (SBP≥140mmHg or diastolic BP 
DBP≥90mmHg) in adults was estimated as ≥20% in 2015 [2]. However, whilst hypertension 
is a major risk factor for coronary heart disease and stroke, the evidence is much weaker for 
an association with cancer [3].
A meta-analysis of ten longitudinal studies published in 2002 found that individuals with 
hypertension had higher risk of total cancer mortality: odds ratio OR=1.23 (95% confidence 
interval (CI) 1.11-1.36), largely explained, based on 13 case-control studies, by a positive 
association for renal cell carcinoma (RCC) mortality: OR=1.75 (1.61-1.90) [4]. The results 
of subsequent studies have confirmed that hypertension is associated with a higher incidence 
of RCC [5–8]. Whilst, hypertension has not attracted much attention as a risk factor for other 
cancers, recent meta-analyses of observational studies, although summarising only 5 to 12 
prospective studies and with large between-study heterogeneity, have reported higher risks 
for endometrial, prostate, postmenopausal breast and colorectal cancer, comparing 
hypertensive with normotensive participants [9–15]. Further, the largest to date prospective 
study examining the association of individual components of the metabolic syndrome 
(including BP measurements) and cancer in over half a million participants from Norway, 
Sweden and Austria: the Metabolic syndrome and Cancer project (Me-Can) [16], reported 
positive associations of high BP with the risk of cancers in locations other than the kidney in 
both men (oropharynx, colon, rectum and anus, lung with larynx and trachea, bladder, 
malignant melanoma, non-melanoma skin cancer) and women (liver, pancreas, corpus uteri, 
cervix, malignant melanoma) [3].
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It is not clear whether the association of hypertension with cancer is causal or it could, at 
least partially, be explained by reverse causality or other biases. It is, however, possible that 
risk factors and mechanisms of pathogenesis are shared by the two conditions. For example, 
it has been hypothesized that predisposition to cancer is increased by chronic inflammation 
[17] and vascular inflammation could be involved in the pathogenesis of hypertension [18]. 
Lipid peroxidation, associated with hypertension and obesity, has also been proposed as a 
mechanism responsible for higher risk of RCC [19]. Further, experimental studies have 
implicated a potential role of the renin-angiotensin-aldosterone system (which regulates BP) 
in the biological processes of cellular proliferation, inflammation, angiogenesis, and tissue 
remodeling [20]. Studies in mice have also provided preliminary evidence that blockade of 
the angiotensin II type 1 receptor attenuates the growth and metastatic potential of RCC 
[21].
In the context of the above considerations, the aim of our study was to further explore the 
association between hypertension and cancer. We examined whether measured SBP and 
DBP were associated with the risk of incident cancer at all anatomical sites in the large and 
well-established European Prospective Investigation into Cancer and Nutrition (EPIC) 
cohort, after taking into account obesity smoking and other lifestyle and dietary factors (for 
both men and women) and indicators of sexual maturation and reproductive life (for 




EPIC is an ongoing, multicentre, prospective cohort study designed to investigate the 
associations between diet, lifestyle, and various medical and environmental risk factors with 
the incidence of cancer and other diseases. The source population (the majority aged 
between 25 and 70 years at the time of enrolment) and data collection methods have been 
described in detail previously [22]. Approval for this study was obtained from the ethical 
review boards of the International Agency for Research on Cancer and from all the EPIC 
participating centres. Written informed consent was obtained from all participants before 
entry into the study.
Figure 1 shows a detailed flow-chart of study participants with exclusions.
Assessment of blood pressure and other variables
SBP and DBP were measured in millimeters of mercury (mmHg) by trained personnel. 
Measurements were obtained during a visit to an EPIC centre and within 6 months of 
recruitment in 91.5% of participants, except in France: all measurements obtained at the 
blood-collection visit, 3.8 years (standard deviation (SD) 1.3) after recruitment; Granada: 
39.2% after 2.0 (0.9) years; San Sebastian: 78.4% after 1.6 (0.7) years; Oxford: 29.3 % after 
0.8 (0.2) years. Two readings (1-5 minutes apart) were performed with a standard mercury 
manometer or oscillometric device on the right arm in a sitting position (after at least 5 
minutes initial resting time). The average value was used as the exposure variable, assuming 
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differences are due to random measurement error. Exceptions were the Danish and Swedish 
centres, where one single measurement was taken in the supine position. Mean BP (MBP) 
was defined as (1/3)*SBP+(2/3)*DBP [23] and not as the mean of SBP and DBP (mid-BP), 
used in the Me-Can study [3]. Self-reported information on treatment with antihypertensive 
medication (at baseline and/or in the past) was available for 264,353 participants (86.9%), of 
which 37,017 (14%) were receiving or had received treatment.
Information on socio-demographics, lifestyle characteristics, medical history and dietary 
intake was collected via questionnaires at the time of recruitment. Weight and height were 
measured at recruitment using a standardised protocol, except for part of the Oxford cohort 
and France, where height and weight were self-reported. Body mass index (BMI) was 
calculated as weight/height2 (kg/m2). Food and nutrient intakes were estimated from 
country-specific baseline dietary questionnaires [22]. A physical activity index was derived 
as previously described [24].
Assessment of cancer
Incident cancer cases were identified through population cancer registries in Denmark, Italy, 
the Netherlands, Spain, Sweden and the United Kingdom. In France, Germany and Greece, a 
combination of methods was used including health insurance records, cancer pathology 
registries and active follow-up of study participants and their next of kin. Cancer incidence 
data were coded according to the International Classification of Diseases for Oncology 
(ICD-O) [25]. The presented analyses are focused on the first primary neoplasm. 
Participants subsequently diagnosed with a second (or third) cancer, were censored at the 
date of diagnosis of the first cancer. We considered a joint group of any cancer and location 
(ICD-O behavioral code 3 (malignant, primary site)) and separate groups for all major 
anatomic sites (excluding rare morphologies), with further subdivisions for specific locations 
or major morphologies (Supplementary Table 1).
Statistical analyses
Hazard ratios (HRs) (95% CIs) were estimated using delayed-entry Cox proportional 
hazards models, with age at recruitment (5-year categories) and EPIC centre (n=25) as 
stratification variables. Origin of time was the date of birth, aligning individuals by birth 
cohort. Entry time was the date of BP measurement. Time of censorship was the date of first 
incidence of cancer (recruitment to 2013), or death, or last complete follow-up, whichever 
occurred first.
The main analyses examined the following exposures: SBP and DBP (considered in separate 
models and each as a continuous (per 10mmHg) variable); hypertension (defined as a 
dichotomous (yes/no) variable, according to BP measurements (SBP≥140mmHg, or 
DBP≥90mmHg) or self-reported information, and antihypertensive treatment in hypertensive 
individuals (a binary variable defined according to self-reported antihypertensive treatment 
(yes/no) for individuals fulfilling the hypertension criteria specified above). The latter 
analysis aimed to examine potential associations of antihypertensive drugs, as exogenous 
chemicals, and cancer. Although the results for hypertension (yes/no) would be useful for 
meta-analyses, the risk estimates per 10 mmHg, based on the complete range of SBP and 
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DBP, would be more informative than a dichotomous simplification. The secondary analyses 
examined SBP and DBP as categorical variables, with categories based on the definitions of 
the American (ASH) [26] and the European Society of Hypertension (ESH) [27] 
(Supplementary Table 2), and MBP, as a continuous variable and also categorised using 
cohort-wide quartiles (cut-points at 88.8, 96.7, 106.0 mmHg). To test for trend, BP 
categories were analysed as continuous variables, after assigning participants an ordinal 
score.
All statistical models were adjusted for the categorical variables listed in Supplementary 
Table 2. Missing values were assigned to separate categories. For pre-menopausal breast 
cancers, analyses were restricted to participants with pre-menopausal status at recruitment 
(if known), or under the age of 46 (for unknown menopausal status) and were not adjusted 
for menopausal status or age at menopause. If breast cancer diagnosis was before 46 years of 
age, participants were considered “cases”, otherwise they were censored at 46 years, if not 
censored by age 46 for death, loss to follow-up or other cancer. For post-menopausal breast 
cancer, analyses were restricted to participants with physiological or surgical menopause at 
recruitment, or with age≥55 years (for unknown menopausal status).
Additionally, associations of BP with cancer were examined in strata according to age (cut-
point at 53 years, the cohort-wide median), sex, BMI (cut-point at 25kg/m2), smoking status 
(ever smokers vs never smokers), alcoholic beverages intake (cut-point at 12g ethanol/day, 
the largest ethanol unit used in Europe) and use of antihypertensive treatment in individuals 
with available information for the stratifying factor. Likelihood ratio tests, comparing nested 
models with and without the addition of interaction terms, were used to test for statistical 
interactions on multiplicative scale. BP categories were included in the interaction models as 
ordinal variables. Examining potential biological interactions was beyond the scope of this 
study.
Sensitivity analyses were also performed, excluding the first two years of follow-up (to 
explore possible reverse causation). Crude estimates of HR (omitting the adjustment 
variables, but retaining the stratification by age at recruitment and study centre) were 
calculated to examine the influence of adjustment.
All analyses were performed with STATA version 13 software. Plots and data summaries 
were generated in R version 3.4.3.
Results and Discussion
Characteristics of study participants
The study cohort consisted of 307,318 individuals (63.4% women), with a mean age 52.5 
(SD=9.9) years at recruitment. During an average follow-up of 13.7 (SD=4.4) years, 39,298 
incident cancers were diagnosed, with major anatomical sites: breast (n=8,154 cases), 
prostate (n=5,848), colorectum (n=4,625) and lung (n=3,229). Mean SBP was 131.5mmHg 
(SD=19.7) and mean DBP was 81.1mmHg (SD=10.9). BP measurements and numbers of 
cancer cases are summarised by country in Supplementary Table 3. Participants with higher 
SBP or DBP were older, more likely to be men, to have low education or physical activity 
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level, to have higher BMI, to have diabetes mellitus and to consume more alcohol and red 
meat, but less fruit and vegetables. Women with higher SBP or DBP were less likely to have 
ever used oral contraceptives. Cohort characteristics are summarised by hypertension and 
treatment status in Table 1 and by BP categories in Supplementary Table 4.
Associations with the risk of malignant cancers
Results from all analyses are included in Supplementary Table 5. The presentation below 
focuses on SBP and DBP examined as continuous variables in adjusted models. Forest plots 
with estimates of HR (95% CI) for SBP and DBP in the total dataset are shown in Figure 2; 
for hypertensive status and antihypertensive treatment in Figure 3 and for sub-groups 
determined by sex, BMI, age at recruitment, smoking status, alcohol and antihypertensive 
treatment are shown in Supplementary Figure 1. There were positive associations of BP with 
malignant cancers in several locations and with some specific morphologies. Analyses of BP 
categories were largely in agreement with the findings for BP examined on a continuous 
scale. The main findings are presented below, within the context of large published studies 
and meta-analyses. Anatomical cites and cancers, for which there was no overall association, 
are presented in Supplementary Results and Discussion.
Kidney cancer and cancers of the renal pelvis and ureter—The results of the 
current analyses confirmed our previous findings [6] of a positive association of BP with the 
risk of RCC: HR=1.12 (1.08-1.17) for SBP and HR=1.23 (1.14-1.32) for DBP (Figure 2). 
We found no evidence for a difference between men (with n=431 cases) and women (n=327) 
(Supplementary Figure 1A,B). As cancers of the renal pelvis and ureter are mainly of 
transitional cell morphology, i.e. different than the parenchymal cell morphology of RCC, 
they were considered as a negative control and, indeed, there was no association with BP in 
the total dataset (n=112). There was, however, an indication for a positive association with 
SBP in the subgroup with BMI>25kg/m2 (n=63): HR=1.16 (1.03-1.32). The risk was also 
higher in treated compared to untreated hypertensive individuals: HR=2.21 (1.18-4.12) 
(Figure 3), although for a small number of cases.
The association of hypertension with a higher risk of RCC is well established. In 1999, 
Grossman et al. reported a higher risk for users of diuretics relative to nonusers: OR=1.55 
(1.42-1.71), based on a meta-analysis of 9 case-control studies, and more than a two-fold 
increased risk, based on three cohort studies [28]. In 2007, a meta-analysis of 18 studies 
reported a higher risk of RCC among hypertensive patients (estimated pooled OR=1.62 
(1.24-2.12)), also for treatment with diuretics and, in women, with non-diuretic drugs [7]. At 
the same time, Weikert et al. reported, based on 250 cases in the EPIC study, that high SBP 
and DBP are associated with a higher risk of RCC, both in men and women and found that 
individuals receiving antihypertensive treatment had higher risk only if hypertension was 
poorly controlled [6]. Earlier, Heath et al. had reported in a large cohort high age-adjusted 
risk-ratio in women: RR=3.1 (1.5-4.3), but not in men: RR=0.8 (0.4-1.3) receiving 
antihypertensive medication, including diuretics [29] and Grossman et al. had reported from 
a meta-analysis of seven case-control studies a high risk in women: averaged OR=2.01 
(1.56-2.67), but slightly lower risk in men OR=1.69 (1.34-2.13), but with heterogeneity 
between the studies [28]. However, Haggström et al. reported for the Me-Can project a 
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higher risk only in men (n=592): HR=1.39 (1.24-1.56) per 10mmHg higher mid-BP, but not 
in women (n=263): HR=1.05 (0.89-1.24) [3], with similar findings for SBP and DBP 
examined separately [30]. Nevertheless, a more recent meta-analysis of 18 prospective 
studies, with a total of 8097 cases, has confirmed an association of history of hypertension 
with kidney cancer: risk ratio estimate RR=1.67 (1.46-1.90) and an association also of SBP 
and DBP in both men and women [8], in agreement with our findings. A potential 
relationship between hypertension and the risk of renal pelvis and ureter cancer is less well 
studied, but an early case-control study reported a positive association for hypertension 
history longer than 5 years: OR=1.3 (1.0-1.8) and, in agreement with our findings, among 
users of antihypertensive drugs: OR=2.4 (1.1-4.9) [31]. However, as antihypertensive 
treatment may be related to the type and severity of hypertension, it is difficult to separate 
their effects in an observational study.
Cancers of the upper aero-digestive tract and lung—We found a positive 
association of BP with the risk of esophageal carcinoma, but more specifically with 
squamous cell carcinoma (SCC) (n=149): HR=1.16 (1.07-1.26) for SBP and HR=1.31 
(1.13-1.51) for DBP and not with esophageal adenocarcinoma (AC) (n=176) (Figure 2). We 
also found a weak positive association for head and neck cancers (89% of which were SCC 
morphology): HR=1.08 (1.04-1.12) for SBP and HR=1.09 (1.01-1.17) for DBP (similarly 
for mouth and oropharynx and for larynx). For mouth and oropharynx, the positive 
associations were statistically significant only in women, in individuals older than 53 years 
at recruitment and for alcohol intake>12g/day and for head and neck cancers and esophageal 
SCC only for alcohol intake>12g/day and not below. There were, however, fewer cases 
among never smokers and the 95% CIs were too wide to make meaningful conclusions for 
smoking (Supplementary Figure 1G,H).
For lung cancer, there was no overall evidence for association of BP with SCC, AC or small 
cell carcinoma morphologies (Figure 2). In subgroup analyses, we observed an inverse 
association of DBP with lung AC among individuals with BMI>25kg/m2 (n=528): HR=0.90 
(0.83-0.98) and a positive association of SBP with lung SCC in individuals receiving 
antihypertensive treatment (n=74): HR=1.14 (1.01-1.28). A weak positive association of 
SBP with the risk of total lung cancer was mainly accountable for by other morphologies 
(predominantly unclassified or large cell): HR=1.06 (1.02-1.09).
Our findings for esophageal cancer are in agreement with the similarly-sized Me-Can 
project, for which Stocks et al. reported a positive association of mid-BP with total 
esophageal cancer (n=285): HR=1.33 (1.13–1.57) per 10mmHg higher BP [3]. Lindkvist et 
al. further showed that this was accountable for by a higher risk of SCC (n=184): HR=1.30 
(1.17-1.44) and not AC (n=114): HR=1.03 (0.89-1.19), with no major differences between 
subgroups of never, former and current smokers [32]. For head and neck cancers, Stocks et 
al. did report for the Me-Can project an association of mid-BP with the risk of cancers of the 
lip, oral cavity and pharynx, but only in men (n=561): HR=1.31 (1.15-1.48) per 10mmHg 
increase, and not in women (n=177): HR=1.05 (0.85-1.28). They also found a positive 
association for the combined group of cancer of the larynx, trachea and lung in men 
(n=2810): HR=1.09 (1.03-1.16) but not in women (n=905): HR=1.00 (0.92-1.10) [3]. Our 
study includes a similar number of lung cancer cases (n=3229), but we have examined 
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separately cancer of the larynx and individual lung morphologies. Whilst smoking is a major 
risk factor for both esophageal and lung SCC cancers and can also lead to hypertension, as 
shown in an animal model [33] and some epidemiological studies [34, 35], we could find a 
positive association with hypertension only for esophageal and not for lung SCC, after 
adjustment for smoking. If there was any residual confounding by smoking, it is likely that 
we would have observed a positive association for lung, as well as for esophageal SCC. In 
fact, we could find no positive association of hypertension with lung SCC even without 
adjustment for confounders (crude HRs in Supplementary Figure 2). Further, a positive 
association for esophageal AC was observed only in unadjusted analyses but was lost after 
adjustment for confounders, indicating that the adjustment, has removed, to a great extent, 
the confounding by smoking. This leads us to conclude that smoking is not likely to explain 
the association of high BP with the risk of SCC in the upper aero-digestive tract. Alcohol, 
however, may have an influence (Supplementary Figure 1I,J), but further investigations are 
needed to clarify our observations.
Gastric and colorectal cancers—We could not find association of BP with the risk of 
gastric cancer (n=738) (including gastric AC (n=403)) in the total cohort (Figure 2). We only 
found a positive association for gastric AC among individuals receiving antihypertensive 
treatment (n=53): HR=1.22 (1.06-1.40) for SBP and HR=1.65 (1.27-2.15) for DBP. We also 
found a weak positive association of DBP with the risk of cancer of the colon (n=3003) 
(75% of which had AC (code 8140/3) morphology): HR=1.06 (1.02-1.10) for DBP, similarly 
for men and women (Supplementary Figure 1B), but not the rectum and rectosigmoid 
junction (n=1622) (81% AC) (Figure 2). There was also a weak positive association of SBP 
with the risk of colorectal cancer (similarly for colon and rectum (including rectosigmoid 
junction)) in men, but not in women (in men colon (n=1304): HR=1.03 (1.00-1.06) and 
rectum (n=876): HR=1.03 (0.99-1.07)). We also found a positive association in the subgroup 
analyses for participants with BMI>25kg/m2 (colon: n=1813, rectum: n=966) and for the 
participants who reported alcohol intake>12g/d (colon: n=1091, rectum: n=685) 
(Supplementary Figure 1C,D,I,J).
Our data are broadly compatible with results from previous large studies, which suggest that 
high BP is associated with the risk of colorectal cancer in men but not in women. In 2001 
Tenenbaum et al. reported, in a cohort of patients with stable angina or previous myocardial 
infarction, higher risk of colon cancer (n=96) in individuals receiving diuretics compared to 
nonusers: HR=2.0 (1.2-3.2) [36]. More recently, in a large case-control study in Italy, 
Pelucchi et al. found that history of treated hypertension was associated with colorectal 
cancer risk in men (n=1310) OR=1.24 (1.03-1.48) but not in women (n=946) OR=0.87 
(0.71-1.06) [37]. Stocks et al., considering SBP, DBP and mid-BP in a prospective study 
(Me-Can), also reported a positive association for cancer of the colon in men (n=1747): 
HR=1.10 (1.03-1.19) per 10mmHg higher mid-BP but not in women (n=1265): HR=0.95 
(0.88-1.02) [3, 38], with similar findings for cancer of the rectum and anus [3]. Esposito et 
al., have subsequently reported in a meta-analysis based on 9 studies, a RR=1.09 (1.01-1.18) 
for high BP, although considering jointly men and women [13]. For gastric AC, Lindkvist et 
al., similar to our total cohort results, could not find in the Me-Can project evidence 
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supporting an association with mid-BP (n=1210), but they did not consider antihypertensive 
treatment [39].
Breast cancer—In our study, representing a cohort with the largest to date number of 
breast cancer cases, we found a weak but statistically significant positive association with 
both, SBP and DBP (n=8154): HR=1.03 (1.01-1.04) for SBP and HR=1.03 (1.01-1.06) for 
DBP. The association was similar for post-menopausal cancers (n=4786), but the number of 
pre-menopausal cancers was considerably smaller and the 95% CIs were too wide to permit 
conclusions. In sub-group analyses, the positive association of SBP with the risk of post-
menopausal breast cancer was retained only in ever smokers (n=2180) and there was some 
suggestion for a positive association of SBP with pre-menopausal breast cancer in women 
with alcohol intake≤12g/day (n=201) (Supplementary Figure 1G,I).
Literature reports on breast cancer are conflicting. In an early case-control study in Italy, 
Soler at al. described a higher risk of breast cancer in women with treated hypertension 
(n=3,406): OR=1.2 (1.1-1.4) and more specifically in post-menopausal (n=2184), at age 55 
years or older (n=1580), in drinking women (n=2,400) and at BMI>25kg/m2 (n=1266) and 
not in pre- and peri-menopausal women [40]. However, Bjorge et al. in the Me-Can project 
did not find associations of SBP or DBP with the risk of incident breast cancer (n=4,862), 
however they reported a higher risk of breast cancer mortality for age≥60 years [41]. 
Similarly, Largent et al., defining high BP as treated hypertension in the California Teachers 
Study cohort (n=4,151), found a higher risk associated with antihypertensive treatment 
longer than 5 years: HR=1.18 (1.02-1.36) [42], but no association with hypertension overall. 
However, in the largest to date meta-analysis (n=11,643), Han et al. (in agreement with an 
earlier meta-analysis [12] and with our findings) have reported a higher risk of breast cancer 
in hypertensive women, based on 18 retrospective case-control studies: RR 1.29 (1.14-1.47) 
and on 12 prospective studies: RR=1.07 (1.01-1.14), but only for post-menopausal women 
(13 studies): RR=1.20 (1.09-1.31) and not for pre-menopausal (9 studies): RR=0.97 
(0.84-1.12) [15].
Endometrial cancer—For cancers located in corpus uteri, we found a weak positive 
association, which could be traced only to AC morphology (code 8140/3): HR=1.06 
(1.01-1.12) for SBP and HR=1.11 (1.02-1.22) for DBP, but not to the endometroid 
morphology (code 8380/3): HR=1.00 (0.96-1.05) for SBP and HR=1.02 (0.93-1.10) for DBP 
(Figure 2). In sub-group analyses, the association for AC morphology was retained only at 
BMI>25kg/m2 and in never smokers (Supplementary Figure 1C,D,G,H). The differences 
between morphologies, however, would need further clarification, as the relative proportions 
of the two morphologies differed considerably between the individual countries in the EPIC 
cohort (Supplementary Table 3).
Large European case-control and cohort studies (n>700 in each), although not accounting 
for specific morphologies, have consistently reported, in agreement with our findings, a 
higher risk of endometrial cancer with high BP [40, 43, 44], especially in obese women [43, 
44], while a relatively smaller case-control study in the United States (n=469) found a higher 
risk only in women receiving thiazide diuretics [45]. Nevertheless, recent meta-analyses, 
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have corroborated a positive association: RR=1.32 (1.12-1.56) (6 prospective studies, 1,1469 
cases) [9], RR=1.81 (1.08–3.03) (5 studies, 3,112 cases) [10].
Cervical cancer—For cervical SCC (n=145), but not for total cervical cancers (n=223), 
we found an inverse association (Figure 2), which was especially pronounced in women with 
BMI>25kg/m2 (n=68): HR=0.81 (0.71-0.93) for SBP and HR=0.74 (0.57-0.95) for DBP 
(Supplementary Figure 1C,D), whilst we found no evidence for association of BP with 
cervical AC (n=37) and a positive association for the remaining morphologies (n=41): 
HR=1.28 (1.10-1.48) for SBP and HR=1.53 (1.17-2.01) for DBP, which would have 
contributed to absence of an overall association for total cervical cancers, but with a small 
number of cases, this could be a chance finding.
In contrast to our findings, Stocks et al. reported a higher risk of total cervical cancer in the 
Me-Can study (n=424): HR=1.17 (1.01-1.34) per 10mmHg higher mid-BP [3]. Further, 
Ulmer et al. examined individual morphological subtypes and reported, similar to 
esophageal cancer, a positive association for cervical SCC (n=337): HR=1.28 (1.05-1.57) 
per SD higher mid-BP, but not for cervical AC (n=59): HR=1.09 (0.65-1.83) [46].
Prostate cancer—Our study, based on a reasonably large number of incident cases 
(n=5,848), provided no evidence for association of SBP or DBP with the risk of prostate 
cancer: HR=0.99 (0.98-1.01) for SBP and HR=1.01 (0.99-1.04) for DBP, except for some 
weak inverse association, mainly with SBP, which was found only in never smokers 
(n=1937): HR=0.97 (0.95-1.00).
Contrary to our findings, the CONOR study (n=1974) [47] has reported a weak positive 
association between SBP and DBP and the risk of prostate cancer and recent meta-have 
confirmed this [11, 14]. Based on 10 studies (n=4343), Esposito et al. reported RR=1.15 
(1.01-1.30) [11] and Gacci et al. (7 studies) reported RR=1.10 (1.01-1.19) [14]. However, 
the Me-Can study (n=6673) [48] found only a positive association of SBP and DBP with 
prostate cancer death, while Stocks et al. reported in the Swedish Construction Workers 
cohort an inverse association with the risk of total prostate cancer (n=10,002) and non-
aggressive tumours (n=2817), but a positive association of DBP with the risk of aggressive 
tumours (n=2402) [49]. In the light of these discrepancies, it would be important to examine 
further the impact of cancer aggressiveness or grading in EPIC, but this was beyond the 
scope of the current study.
Blood and lymphoid cancers—Our data revealed an inverse association of BP with the 
risk of all-type lymphomas (n=1058), and specifically with non-Hodgkin lymphomas 
(n=882): HR 0.96 (0.92-0.99) for SBP and borderline for DBP: HR=0.95 (0.89-1.02), whilst 
we found no evidence for association with leukaemia (n=1308), or specifically with multiple 
myeloma (n=475) (Figure 2).
In the Me-Can study, Nagel et al. considered a total of 2,751 cases of myeloid and lymphoid 
neoplasms and their results did not support associations with mid-BP, except for a 
suggestion, based on a small number of cases (n=46), for an inverse association with the risk 
of T-cell non-Hodgkin lymphomas in men: HR=0.54 (0.29-1.01) [50]. Lymphoid cells are 
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closely involved in inflammatory processes and recent studies have specifically linked T-cell 
subtypes with vascular remodelling and the development of hypertension [51], so there may 
be some mechanistic explanation, but this would need a more detailed investigation.
Skin cancer—We found evidence for a positive association with the risk of skin SCC for 
DBP (n=1399): HR=1.07 (1.02-1.13) and for antihypertensive treatment among hypertensive 
individuals: HR=1.45 (1.22-1.72).
The Me-Can project also reported higher risk of skin SCC, but only in men (n=566): 
HR=1.11 (0.95–1.31) for one SD higher mid-BP and not in women (n=286): HR=0.95 
(0.76-1.19) [52]. Several studies have also reported higher risk in association with 
antihypertensive drugs, especially diuretics [53], but there were no sufficient treatment 
details in EPIC to explore further.
Sensitivity analyses
Excluding the first two years of follow-up did not have material influence on the findings 
(Supplementary Figure 2), except for abolishing the inverse association for cervical SCC 
(without changing it to positive), which may be the result of selection bias introduced by the 
exclusion. However, crude HRs (unadjusted) (Supplementary Figure 3) had indicated some 
associations, which were lost or mitigated after adjustment for confounders. Thus, crude 
HRs indicated positive associations of SBP and DBP not only with esophageal SCC or the 
endometroid cancer morphology in corpus uteri, but also of the AC morphology in both 
locations, and further positive associations of DBP with gastric cancer (total and AC 
morphology) and of SBP, not only DBP, with cancers of the rectum and rectosigmoid 
junction, as well as with colon cancer. Additionally, crude HRs indicated positive 
associations of SBP and DBP with bladder cancer, of SBP with liver cancer (accountable for 
only by HCC) and of DBP with multiple myeloma. In addition, in the absence of adjustment 
for confounders a weak inverse association was observed for SBP with prostate cancer (SBP 
only) and DBP with lung AC. Associations observed only in crude and not in adjusted HR 
estimates suggest that the differences in the selection of adjustment variables in our and 
other studies may be responsible for some of the discrepancies in the findings. Of note, we 
have included adjustment for dietary factors, information on which was either not available 
or not included in the analyses in other published studies. This may be of particular 
relevance to cancers of the gastrointestinal tract. Similarly, we have used detailed 
information on reproductive factors in women, although adjustment did not affect our 
findings for breast and cervical cancers (Supplementary Figure 3).
Strengths and limitations
Our study has several strengths and limitations. Major advantages are the prospective design 
and the large sample size, including several European countries. Furthermore, BP was 
measured by trained personnel and was not self-reported. Detailed information on lifestyle, 
diet and, in women, reproductive history and hormonal treatments was also available, 
enabling adjustment for potential confounders and shared risk factors.
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The main limitation of our study is that BP was measured only at one timepoint. Moreover, 
specific information on the type of antihypertensive medications in treated individuals was 
unavailable. Theoretically, antihypertensive treatment could lead to a lower “observed” BP, 
i.e. measured during the investigation, compared to the “underlying” BP, i.e. the BP that 
could be reached without treatment. If high BP is causally associated with cancer, 
controlling BP would mitigate the association, but if high BP and cancer share common 
mechanisms, the association would remain when BP is controlled, unless treatment targets 
the mechanism of BP development. In practice, however, a single timepoint measurement 
may not be representative of the commonly “observed” BP and this applies to untreated and 
treated individuals alike. Individuals receiving treatment are also likely to have a more 
sustained high BP, confirmed by a doctor. Treated individuals in our study showed, indeed, 
considerably higher SBP (mean difference 19.8mmHg (95% CI 19.6-20.1)) and DBP 
(9.5mmHg (9.4-9.6)) compared to cohort participants without antihypertensive treatment 
and even showed marginally higher SBP (1.2mmHg (1.0-1.4)) and DBP (0.4mmHg 
(0.3-0.5)) compared to untreated hypertensive individuals (self-reported or with “observed” 
high BP (Table 1)). Therefore, when there was a positive association for both hypertension 
and antihypertensive treatment, as for kidney cancer, we could not discriminate associations 
related to the severity and duration of high BP from association related to the administration 
of antihypertensive medication (Figure 3). Nevertheless, a positive association only for 
treated compared to untreated hypertension, as for cancers of the renal pelvis and ureter, 
might be more suggestive of the involvement of treatment (Figure 3). There is a growing 
body of literature evaluating associations between antihypertensive medication and cancer 
development, but with overall inconclusive findings. An involvement of drugs in cancer 
pathogenesis is possible, because they are exogenous chemical compounds administered 
often for very long time [54], but we have not reviewed this literature, because our study 
could not contribute reliably to the debate.
Finally, information about potential confounders and shared risk factors was self-reported, 
which may have contributed to misclassification bias and there are always potentially 
unmeasured risk factors, which may result in residual confounding.
Conclusions
The results of our study, involving over 300,000 participants, are largely compatible with 
published studies. We confirmed a positive association between BP and RCC and 
additionally found a positive association of BP with malignant cancers in several anatomical 
cites, including postmenopausal breast and colon cancers, and with specific morphologies, 
i.e. SCC in the upper aero-digestive tract and the skin or AC in corpus uteri and other 
unspecified locations. We also found an inverse association of BP with the risk of non-
Hodgkin lymphomas and cervical SCC. These associations, however, are mainly weak and 
future research is required to clarify potential shared mechanisms. Admittedly, observations 
based on smaller number of cases could be chance findings, but they could also give some 
directions for further studies.
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AC adenocarcinoma
ASH American Society of Hypertension
BP blood pressure
CI confidence interval
DBP diastolic blood pressure
EPIC European Prospective Investigation into Cancer and Nutrition
ESH European Society of Hypertension
HCC hepatocellular carcinoma
HR hazard ratio
MBP mean blood pressure, derived as (1/3)*SBP+(2/3)*DBP (used in the 
current study)
Me-Can Metabolic syndrome and Cancer project
mid-BP mid-blood pressure, derived as the mean of SBP and DBP (used in 
Me-Can)
OR odds ratio
RCC renal cell carcinoma
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SBP systolic blood pressure
SCC squamous cell carcinoma
SD standard deviation
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Our large prospective study strengthens the evidence for weak positive associations of 
blood pressure with the risk of cancers in several locations: kidney, colon and post-
menopausal breast cancers, and with some specific morphologies: squamous cell 
carcinoma (SCC) in the upper aero-digestive tract and skin and adenocarcinoma in 
corpus uteri. We also report weak inverse associations with lymphomas and cervical 
SCC. Our findings render plausible a hypothesis of shared mechanisms for hypertension 
and cancer development.
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Is there a link between high blood pressure and cancer? In this large, prospective study, 
the authors found that hypertension is indeed associated with a moderate increase in risk 
for several cancers, including renal, esophageal, head and neck, skin, colon, post-
menopausal breast cancer, and uterine cancer. These results may potentially enhance 
screening and risk assessment. Further research may also identify shared mechanisms for 
both hypertension and cancer, such as inflammation, lipid peroxidation, etc.
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Figure 1. Flow diagram for EPIC participants included in the current study
n – number of participants; ca – number of cancer cases.
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Figure 2. Forest plot of hazard ratios for continuous systolic and diastolic blood pressure
AC – adenocarcinoma; CNS – central nervous system; HCC – hepatocellular carcinoma; 
SCC – squamous cell carcinoma; SmallCC – small cell carcinoma; Vertical order – 
determined by the hazard ratio estimates for systolic blood pressure (SBP) of the main 
anatomical locations (dot symbols), each followed by the relevant specific locations or 
morphologies marked with ^ (+ symbols) (other locations, not included in those specified, 
are shown last); Hazard ratios – estimates (95% confidence intervals) (per 10mmHg higher 
blood pressure) derived from Cox proportional hazards models, stratified by study centre 
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and age at recruitment (5-year categories) and adjusted for potential confounders and risk 
factors listed in Supplementary Table 2). For cervical AC (n=37): HR=0.96 (0.79-1.17) for 
SBP and HR=0.84 (0.59-1.19) for DBP and for other morphology in the cervix (non-SCC 
and non-AC) (n=41): HR=1.28 (1.10-1.48) for SBP and HR=1.53 (1.17-2.01) for DBP 
(considered only in the main analyses and excluded to avoid the larger confidence intervals 
dominating the plot); * p<0.05, ** p<0.005.
Christakoudi et al. Page 23













Figure 3. Forest plot of hazard ratios for dichotomous hypertension and antihypertensive 
treatment
AC – adenocarcinoma; CNS – central nervous system; HCC – hepatocellular carcinoma; 
SCC – squamous cell carcinoma; SmallCC – small cell carcinoma; Hypertension – defined 
as systolic blood pressure (SBP) ≥140 mmHg, or diastolic BP (DBP) ≥90 mmHg at the BP 
measurement visit, or self-reported history of hypertension; Antihypertensive treatment 
status – either self-reported or no treatment assumed if there was self-reported absence of 
diagnosis of hypertension; Cases – numbers per group (hypertension / no hypertension & 
treated / untreated hypertension); Vertical order – determined by the hazard ratio estimates 
for SBP of the main anatomical locations (dot symbols), each followed by the relevant 
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specific locations or morphologies marked with ^ (+ symbols) (as per Figure 2) (other 
locations, not included in those specified, are shown last); Hazard ratios – estimates (95% 
confidence intervals) (per 10 mmHg higher BP) were derived from Cox proportional hazards 
models, stratified by study centre and age at recruitment (5-year categories) and adjusted for 
potential confounders and risk factors listed in Supplementary Table 2. For cervical AC 
(n=37): HR=1.23 (0.58-2.06) and for other morphology in the cervix (non-SCC and non-
AC) (n=41): HR=1.82 (0.92-3.63) (considered only in the main analyses and omitted from 
the plot to avoid the larger confidence intervals dominating the plot); * p<0.05, ** p<0.005.
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Table 1
Baseline demographic, lifestyle and reproductive characteristics by hypertension and 
treatment status
Characteristics (men and 
women)
Total No hypertension Hypertension Untreated 
hypertension
Treated hypertension
Cohort size 307318 174179 133139 73714 37017
Female 194727 (63.4) 117264 (67.3) 77463 (58.2) 41779 (56.7) 23736 (64.1)
Age at recruitment, years 52.5 (9.9) 49.8 (9.8) 56.1 (8.7) 54.9 (8.6) 57.8 (7.6)
Body Mass Index, kg/m2 25.8 (4.2) 24.8 (3.7) 27.1 (4.5) 26.7 (4.3) 28.2 (4.7)
Alcohol intake, g/day 12.4 (17.1) 11.2 (15.2) 13.9 (19.2) 15.4 (20.2) 12.3 (18.0)
Fruit consumption, g/day 230.6 (176.7) 235.2 (182.3) 224.6 (169.0) 226.3 (172.6) 230.9 (164.4)
Vegetable consumption, g/day 200.9 (145.4) 205.0 (149.9) 195.6 (139.2) 190.9 (138.4) 195.9 (143.6)
Red meat consumption, g/day 48.2 (36.3) 46.5 (35.7) 50.5 (37.0) 53.1 (37.7) 47.4 (34.0)
Blood pressure, mmHg
Systolic blood pressure 131.5 (19.7) 119.4 (10.9) 147.3 (17.4) 146.7 (15.9) 147.9 (20.0)
Diastolic blood pressure 81.1 (10.9) 75.2 (7.5) 88.8 (9.8) 88.6 (9.1) 89.0 (10.6)
Diabetes
Self-reported diabetes 8588 (2.8) 2516 (1.4) 6072 (4.6) 2410 (3.3) 3067 (8.3)
Missing information 30147 (9.8) 16247 (9.3) 13900 (10.4) 615 (0.8) 657 (1.8)
Smoking status
Never smoker 141931 (46.2) 80450 (46.2) 61481 (46.2) 33057 (44.8) 18603 (50.3)
Former smoker 86314 (28.1) 45575 (26.2) 40739 (30.6) 21901 (29.7) 11154 (30.1)
Current smoker (≤ 20 pack-years) 32226 (10.5) 21711 (12.5) 10515 (7.9) 6539 (8.9) 2716 (7.3)
Current smoker (> 20 pack-years) 34907 (11.4) 19428 (11.2) 15479 (11.6) 9777 (13.3) 3655 (9.9)
Missing information 11940 (3.9) 7015 (4.0) 4925 (3.7) 2440 (3.3) 889 (2.4)
Physical activity
Inactive 67194 (21.9) 32680 (18.8) 34514 (25.9) 16013 (21.7) 11191 (30.2)
Moderately inactive 100295 (32.6) 57476 (33.0) 42819 (32.2) 23828 (32.3) 12268 (33.1)
Moderately active 70977 (23.1) 42530 (24.4) 28447 (21.4) 16954 (23.0) 7300 (19.7)
Active 62152 (20.2) 36956 (21.2) 25196 (18.9) 15696 (21.3) 6021 (16.3)
Missing information 6700 (2.2) 4537 (2.6) 2163 (1.6) 1223 (1.7) 237 (0.6)
Education
None 9377 (3.1) 3478 (2.0) 5899 (4.4) 2863 (3.9) 2973 (8.0)
Primary school completed 90254 (29.4) 43392 (24.9) 46862 (35.2) 25274 (34.3) 14288 (38.6)
Technical/professional school 77398 (25.2) 43025 (24.7) 34373 (25.8) 18676 (25.3) 9033 (24.4)
Secondary school 53830 (17.5) 35179 (20.2) 18651 (14.0) 11377 (15.4) 4730 (12.8)
Longer education (inc. 
University)
67606 (22.0) 43999 (25.3) 23607 (17.7) 14246 (19.3) 5875 (15.9)
Missing information 8853 (2.9) 5106 (2.9) 3747 (2.8) 1278 (1.7) 118 (0.3)
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Characteristics (men and 
women)
Total No hypertension Hypertension Untreated 
hypertension
Treated hypertension
Age at first menstrual period *
< 12 years 27085 (13.9) 16544 (14.1) 10541 (13.6) 5521 (13.2) 3116 (13.1)
>=12 and < 15 years 125828 (64.6) 76353 (65.1) 49475 (63.9) 27400 (65.6) 15450 (65.1)
>= 15 years 32391 (16.6) 17996 (15.3) 14395 (18.6) 7842 (18.8) 4618 (19.5)
Missing information 9423 (4.8) 6371 (5.4) 3052 (3.9) 1016 (2.4) 552 (2.3)
Age at first full term 
pregnancy*
≤ 21 years 36839 (18.9) 20636 (17.6) 16203 (20.9) 8514 (20.4) 5607 (23.6)
> 21 and ≤ 30 years 106230 (54.6) 62619 (53.4) 43611 (56.3) 23884 (57.2) 13515 (56.9)
≥ 30 years 15709 (8.1) 9715 (8.3) 5994 (7.7) 3391 (8.1) 1689 (7.1)
Missing information 35949 (18.5) 24294 (20.7) 11655 (15.0) 5990 (14.3) 2925 (12.3)
Full-term pregnancies *
None 25571 (13.1) 16963 (14.5) 8608 (11.1) 4966 (11.9) 2397 (10.1)
One 28796 (14.8) 17156 (14.6) 11640 (15.0) 6350 (15.2) 3656 (15.4)
Two 75357 (38.7) 45696 (39.0) 29661 (38.3) 16246 (38.9) 9280 (39.1)
Three 33031 (17.0) 18740 (16.0) 14291 (18.4) 7483 (17.9) 4664 (19.6)
Four or more 14897 (7.7) 7360 (6.3) 7537 (9.7) 3601 (8.6) 2832 (11.9)
Missing information 17075 (8.8) 11349 (9.7) 5726 (7.4) 3133 (7.5) 907 (3.8)
Menopausal status *
Pre-menopausal 58190 (29.9) 45853 (39.1) 12337 (15.9) 7856 (18.8) 2450 (10.3)
Post-menopausal 96806 (49.7) 46876 (40.0) 49930 (64.5) 25486 (61.0) 16640 (70.1)
Peri-menopausal or unknown 33371 (17.1) 21490 (18.3) 11881 (15.3) 6918 (16.6) 3292 (13.9)
Surgical post-menopausal 6360 (3.3) 3045 (2.6) 3315 (4.3) 1519 (3.6) 1354 (5.7)
Age at menopause *
< 40 years 4301 (2.2) 2106 (1.8) 2195 (2.8) 1067 (2.6) 769 (3.2)
≥ 40 and ≤ 46 years 18912 (9.7) 9058 (7.7) 9854 (12.7) 4754 (11.4) 3650 (15.4)
> 46 and ≤ 50 years 31996 (16.4) 15578 (13.3) 16418 (21.2) 8510 (20.4) 5579 (23.5)
> 50 and ≤ 56 years 29427 (15.1) 13238 (11.3) 16189 (20.9) 8327 (19.9) 5619 (23.7)
> 56 years 1997 (1.0) 753 (0.6) 1244 (1.6) 595 (1.4) 469 (2.0)
Missing or not applicable 108094 (55.5) 76531 (65.3) 31563 (40.7) 18526 (44.3) 7650 (32.2)
Oral contraceptive use *
Never 82568 (42.4) 43393 (37.0) 39175 (50.6) 20706 (49.6) 12755 (53.7)
Former 91622 (47.1) 58870 (50.2) 32752 (42.3) 18294 (43.8) 9916 (41.8)
Current 10050 (5.2) 7434 (6.3) 2616 (3.4) 1829 (4.4) 594 (2.5)
Missing information 10487 (5.4) 7567 (6.5) 2920 (3.8) 950 (2.3) 471 (2.0)
Hormone replacement therapy 
*
Never 129049 (66.3) 79952 (68.2) 49097 (63.4) 26920 (64.4) 14842 (62.5)
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Characteristics (men and 
women)
Total No hypertension Hypertension Untreated 
hypertension
Treated hypertension
Former 16259 (8.3) 8638 (7.4) 7621 (9.8) 3937 (9.4) 2598 (10.9)
Current 30133 (15.5) 17724 (15.1) 12409 (16.0) 6596 (15.8) 3891 (16.4)
Missing information 19286 (9.9) 10950 (9.3) 8336 (10.8) 4326 (10.4) 2405 (10.1)
*
Reproductive characteristics in women; Categorical variables: number of individuals (percentage from total number in category (for reproductive 
factors in women only)); Continuous variables: mean (standard deviation).
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